Sanofi Posts Strong 2025 Sales and EPS Growth, Sets High-Single-Digit Outlook for 2026
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sanofi ( (SNY) ) just unveiled an announcement.
On January 29, 2026, Sanofi reported that in 2025 it delivered strong top- and bottom-line growth, with full-year net sales rising 9.9% at constant exchange rates to €43.6 billion and business EPS advancing 15.0% to €7.83, indicating profitability improving faster than revenue. Fourth-quarter 2025 sales grew 13.3% at constant exchange rates to €11.3 billion and business EPS climbed 26.7% to €1.53, driven by a 49.4% surge in revenue from new pharma launches to €1.1 billion—led by Ayvakit and ALTUVIIIO—and a 32.2% increase in Dupixent sales to €4.2 billion, while vaccines declined modestly and higher R&D and SG&A spending supported the launch engine and pipeline. The company highlighted robust pipeline momentum with ten regulatory approvals across immunology and rare diseases, multiple positive phase 3 readouts, and new late-stage starts, and it reinforced its capital allocation strategy through the announced Dynavax acquisition, completion of the Vicebio acquisition, a €5 billion share buyback, and a proposed 5.1% dividend increase to €4.12 per share. Sanofi also underscored strategic moves to shape its operating environment, including an agreement with the U.S. government to reduce medicine costs while backing innovation and leadership in an industry working group on biopharma life-cycle assessment, and it guided for 2026 sales to grow at a high single-digit rate at constant exchange rates with business EPS rising slightly faster, supported in part by a planned €1 billion share buyback program, signaling continued profitable growth and confidence in its mid-term outlook.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score reflects its strong earnings performance and attractive valuation, which are the most significant factors. The company’s financial stability and positive earnings call guidance further support the score, despite some technical analysis indicators suggesting a neutral trend.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is a global biopharmaceutical company headquartered in Paris, focused on prescription medicines, specialty care (including immunology, rare diseases, and oncology), and vaccines. Its portfolio and pipeline are driven by blockbuster products such as Dupixent, new pharma launches like Ayvakit and ALTUVIIIO, and a broad vaccines franchise, with a strong commercial footprint in the United States, Europe, and key emerging markets including China.
Average Trading Volume: 2,639,735
Technical Sentiment Signal: Hold
Current Market Cap: $115.5B
Learn more about SNY stock on TipRanks’ Stock Analysis page.
